These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21115937)

  • 1. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Capponi G; Canepa G; Casazza S; Bandelloni R; Tamagno S; Puntoni M
    Anticancer Res; 2010 Nov; 30(11):4761-5. PubMed ID: 21115937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC).
    Matsuyama H; Ikemoto K; Eguchi S; Oga A; Kawauchi S; Yamamoto Y; Kawai Y; Matsumoto H; Hara T; Nagao K; Sakano S; Sasaki K
    BJU Int; 2014 Apr; 113(4):662-7. PubMed ID: 23890221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.
    Mengual L; Marín-Aguilera M; Ribal MJ; Burset M; Villavicencio H; Oliver A; Alcaraz A
    Eur Urol; 2007 Sep; 52(3):752-9. PubMed ID: 17379395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?
    Bollmann M; Heller H; Bánkfalvi A; Griefingholt H; Bollmann R
    BJU Int; 2005 Jun; 95(9):1219-25. PubMed ID: 15892805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-risk urothelial carcinoma: an unresolved problem?
    Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
    Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bladder cancer biomarkers].
    Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
    Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?
    Gakis G; Kruck S; Stenzl A
    Curr Opin Urol; 2010 Sep; 20(5):388-92. PubMed ID: 20657287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
    Int J Urol; 2014 Oct; 21(10):968-72. PubMed ID: 24947145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.
    Simoneau M; LaRue H; Aboulkassim TO; Meyer F; Moore L; Fradet Y
    Oncogene; 2000 Dec; 19(54):6317-23. PubMed ID: 11175346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
    Szarvas T
    Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
    Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
    Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic methods in the diagnosis of invasive bladder cancer.
    Krause FS; Feil G; Zumbrägel A; Bichler KH
    Anticancer Res; 2000; 20(6D):5015-21. PubMed ID: 11326660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer.
    Nguyen CT; Litt DB; Dolar SE; Ulchaker JC; Jones JS; Brainard JA
    Urology; 2009 Feb; 73(2):347-50. PubMed ID: 19022486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.